Feb 23, 2023 7:00am EST Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
Feb 22, 2023 7:00am EST Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Jan 09, 2023 7:00am EST Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
Dec 08, 2022 6:30am EST Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
Dec 02, 2022 7:30am EST Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors